LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 106 filers reported holding LYELL IMMUNOPHARMA INC in Q3 2023. The put-call ratio across all filers is 0.22 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,963,520 | -35.8% | 2,733,462 | -1.3% | 0.00% | – |
| Q1 2024 | $6,175,454 | +14.1% | 2,769,262 | -0.7% | 0.00% | – |
| Q4 2023 | $5,410,131 | +29.3% | 2,788,727 | -2.1% | 0.00% | – |
| Q3 2023 | $4,185,716 | -54.0% | 2,847,426 | -0.6% | 0.00% | -100.0% |
| Q2 2023 | $9,108,945 | -34.1% | 2,864,448 | -51.1% | 0.00% | 0.0% |
| Q1 2023 | $13,830,566 | +34.1% | 5,860,410 | +97.2% | 0.00% | 0.0% |
| Q4 2022 | $10,310,658 | -57.3% | 2,971,371 | -9.8% | 0.00% | -66.7% |
| Q3 2022 | $24,150,000 | +32.2% | 3,294,629 | +17.6% | 0.00% | +50.0% |
| Q2 2022 | $18,266,000 | +45.7% | 2,801,531 | +12.9% | 0.00% | +100.0% |
| Q1 2022 | $12,536,000 | +52.5% | 2,482,323 | +133.6% | 0.00% | 0.0% |
| Q4 2021 | $8,223,000 | +46.5% | 1,062,453 | +180.1% | 0.00% | – |
| Q3 2021 | $5,614,000 | +39.8% | 379,300 | +53.4% | 0.00% | – |
| Q2 2021 | $4,015,000 | – | 247,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MWG Management Ltd. | 20,162,332 | $69,963,292 | 35.72% |
| Orland Properties Ltd | 15,093,969 | $52,376,072 | 27.91% |
| Foresite Capital Management IV, LLC | 10,000,000 | $34,700,000 | 14.82% |
| MIC Capital Management UK LLP | 3,060,569 | $10,620,174 | 2.10% |
| Alphabet Inc. | 5,865,125 | $20,351,984 | 1.18% |
| HSG Holding Ltd | 3,045,997 | $10,569,610 | 1.07% |
| Artal Group S.A. | 700,000 | $2,429 | 0.14% |
| Eagle Health Investments LP | 100,000 | $347,000 | 0.08% |
| Virtus ETF Advisers LLC | 39,345 | $136,527 | 0.07% |
| BBR PARTNERS, LLC | 164,041 | $569,222 | 0.06% |